FOCINVEZ Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Focinvez, and what generic alternatives are available?
Focinvez is a drug marketed by Steriscience and is included in one NDA. There are two patents protecting this drug.
This drug has two patent family members in two countries.
The generic ingredient in FOCINVEZ is fosaprepitant dimeglumine. There are eleven drug master file entries for this compound. Twenty-three suppliers are listed for this compound. Additional details are available on the fosaprepitant dimeglumine profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Focinvez
A generic version of FOCINVEZ was approved as fosaprepitant dimeglumine by FRESENIUS KABI USA on June 9th, 2016.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for FOCINVEZ?
- What are the global sales for FOCINVEZ?
- What is Average Wholesale Price for FOCINVEZ?
Summary for FOCINVEZ
| International Patents: | 2 |
| US Patents: | 2 |
| Applicants: | 1 |
| NDAs: | 1 |
| Finished Product Suppliers / Packagers: | 3 |
| What excipients (inactive ingredients) are in FOCINVEZ? | FOCINVEZ excipients list |
| DailyMed Link: | FOCINVEZ at DailyMed |
US Patents and Regulatory Information for FOCINVEZ
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Steriscience | FOCINVEZ | fosaprepitant dimeglumine | SOLUTION;INTRAVENOUS | 216686-001 | Aug 22, 2023 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | |||
| Steriscience | FOCINVEZ | fosaprepitant dimeglumine | SOLUTION;INTRAVENOUS | 216686-001 | Aug 22, 2023 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for FOCINVEZ
See the table below for patents covering FOCINVEZ around the world.
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| Slovenia | 3487505 | ⤷ Sign Up | |
| South Korea | 102592614 | ⤷ Sign Up | |
| European Patent Office | 4223297 | ADMINISTRATION ET DOSAGE DE DIAMINOPHÉNOTHIAZINES (ADMINISTRATION AND DOSAGE OF DIAMINOPHENOTHIAZINES) | ⤷ Sign Up |
| Spain | 2946165 | ⤷ Sign Up | |
| Finland | 3487505 | ⤷ Sign Up | |
| >Country | >Patent Number | >Title | >Estimated Expiration |
Supplementary Protection Certificates for FOCINVEZ
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 0748320 | 08C0019 | France | ⤷ Sign Up | PRODUCT NAME: FOSAPREPITANT DIMEGLUMINE; REGISTRATION NO/DATE: EU/1/07/437/001 20080111 |
| 0748320 | SPC/GB08/021 | United Kingdom | ⤷ Sign Up | PRODUCT NAME: FOSAPREPITANT AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, IN PARTICULAR THE BIS(N-METHYL-D-GLUCAMINE)SALT; REGISTERED: UK EU/1/07/437/001 20080111; UK EU/1/07/437/002 20080111 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2024 - 2025
NCE-1 Patent Challenge Dates 2024 - 2025
Trigger-based marketing for the life sciences
Get DrugPatentWatch Business Intelligence Reports at Amazon.com
DrugChatter - AI-based answers to questions about drugs
RxJam - Digital Marketing for Life Sciences
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2024, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch
Follow DrugPatentWatch:
